NCT03164005

Brief Summary

The investigators will enroll about 120 subjects from the hospital's healthcare center. The investigators will collect the basic informations, blood pressure, body mass index, fasting blood glucose and fasting blood lipids of each subject. The investigators will collect the blood samples and then test them for fasting insulin levels, VEGF-B levels, the gene promoter region methylation status and the genomic protein methylation levels of the VEGF-B gene of the cells，and finally do the statistical analysis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
194

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 20, 2017

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

May 13, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 23, 2017

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

April 8, 2021

Status Verified

April 1, 2021

Enrollment Period

4 months

First QC Date

May 13, 2017

Last Update Submit

April 5, 2021

Conditions

ObesityMetabolic Disease

Keywords

VEGF-B

Outcome Measures

Primary Outcomes (1)

  • Fasting insulin and blood VEGF-B levels

    To investigate the relationship between blood pressure, BMI, fasting blood glucose, fasting blood lipids and fasting insulin and blood VEGF-B levels.

    3 days

Secondary Outcomes (1)

  • The methylation status of VEGF-B gene promoter region and VEGF-B genomic protein methylation level .

    7 days

Study Arms (2)

Group 1

subjects without metabolic diseases

Group 2

subjects with metabolic diseases

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

subjects without metabolic diseases , subjects with metabolic diseases

You may not qualify if:

  • subjects with active history insulin treatment; and female participant pregnant at the time of recruitment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

Plasma，Peripheral blood mononuclear cells

MeSH Terms

Conditions

ObesityMetabolic Diseases

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Chen Lulu

    Department of Endocrinology, Union Hospital,Tongji Medical College, Huazhong University of Science and Technology

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Endocrinology

Study Record Dates

First Submitted

May 13, 2017

First Posted

May 23, 2017

Study Start

April 20, 2017

Primary Completion

September 1, 2017

Study Completion

March 1, 2018

Last Updated

April 8, 2021

Record last verified: 2021-04

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)